-
Clinical Trials & Development3 weeks agoVaxcyte’s pneumococcal jab exceeds expectations
Shares in Vaxcyte have rocketed on phase 3 trial data for its pneumococcal vaccine VAX-31 that suggests it could take on rivals from Pfizer and MSD.
-
Clinical Trials & Development3 weeks agoVaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data
The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first...
-
Clinical Trials & Development3 weeks agoBiogen’s big lupus bet gets boost from new durability data for skin disease
All signs continue to point forward for Biogen’s initial foray into lupus, as litifilimab elicited clear or almost clear skin within one year in patients with...
-
Clinical Trials & Development3 weeks agoVaxcyte rises as pneumococcal shot establishes ‘new competitive moat’ vs. Pfizer, Merck
VAX-31 beat Pfizer and Merck’s established pneumococcal conjugate vaccines in a Phase 3 trial, exceeding investors’ most ambitious scenario and setting Vaxcyte up to challenge the...
-
Clinical Trials & Development3 weeks agoSTAT+: Pharmalittle: We’re reading about a Vaxcyte pneumococcal shot, increasing pharma M&A, and more
Vaxcyte said its pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up a competition with Pfizer and Merck
-
Clinical Trials & Development3 weeks agoSTAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market
Vaxcyte said its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the biotech to compete with Pfizer and Merck.
-
Clinical Trials & Development3 weeks agoSTAT+: Divergent trial results on cancer vaccines have the field grappling with hard questions
A melanoma vaccine succeeded in a late-stage clinical trial. The question now is whether other cancer vaccines will work — and whether mRNA is up to the...
-
Clinical Trials & Development4 weeks agoTen Blood Markers Could Predict Survival in Multiple Myeloma, Study of 812 Patients Finds
Multiple myeloma, an incurable cancer of the bone marrow’s plasma cells, has long defied doctors’ attempts to predict its course. Patients with what looks like the...
-
Clinical Trials & Development4 weeks agoBiogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase...
-
Clinical Trials & Development4 weeks agoNew diabetes and obesity studies making waves at EASD
As the EASD congress draws to a close, here's a round-up of some of the other clinical trials in diabetes and obesity that drew our attention.
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
